Wellcome responds to US mRNA vaccine funding cuts
Wellcome's Alex Pym responds to the US Health Department's decision to cut $500m in funding for mRNA vaccines
1-minute read
1-minute read
Alex Pym, Director of Infectious Disease at Wellcome, said:
"mRNA vaccine technology has been in development for decades. It has been shown to be safe and effective against infectious diseases. These vaccines can be adapted to different diseases or variants, and could be used to protect those in areas where these diseases are most prevalent and have devastating impacts.
"The US has been a global leader in vaccine R&D and the loss of this funding could be felt worldwide. Continued investment in this area is vital to ensure we fully realise the potential of these promising technologies to tackle existing and emerging diseases.”
Tags
